Progenie molecular has been recognized with the PYME innovadora seal. In this way, our intense research activity in the molecular diagnostic field is certified.
This investigation line focuses on the acquisition of new products that allow the detection of virus, bacteria, fungi and parasites in a sensible and efficent way. We are currently putting great effort to develop detection systems for the bacteria resistances, as the appearance of organisms resistent to antibiotics is a first-rate healthy problem.
This line of research has made possible the development of products that enables the detection of polymorphism related to genetic diseases, such as the thrombophilia, hemochromatosis and Alzheimer.
This line of investigation has been realized in two product lines. On one hand the RealType line that inlcudes exclusive products of our company, and on the other hand the Thrombo inCode y Cardio inCode products jointly developped with Gendiag and Ferrer inCode.
This line allows the incorporation of new genetic diseases in our catalogue. Thanks to the incorporation of the new generation sequencing (NGS) we are able to conduct de diagnostic of one hundred multigenic diseases through the study of selected genes panels.
Progenie molecular develops softwares called BioVisor that easy the interpretation of results obtained with the RealCycler products (pathogens detection and quantification) and RealType (study of point mutations through genotype assays for real-time PCR).
Likewise, we develop softwares that allow the study of mutations through massive sequencing and arrays (BioVisor NGS). We have also developped the Progestor software that enables the clinical sample and results management.
In our laboratory we frequently discover changes in the DNA that had not been previously described. This leads to the opportunity of realizing an activity of basic investigation that materializes in scientific publications and communications in congresses.
We cooperate with the international scientific community in registring these mutations in the genetic databases in order to help in diagnosticating patients all over the world.